Abstract
A significant proportion of patients present with the immune reconstitution inflammatory syndrome (IRIS) after commencing antiretroviral therapy (ART). This syndrome is most frequently associated with infective causes. The lack of evidence-based treatment guidelines poses challenges in the management of these patients. Alternative causes for deterioration should be excluded, and optimization of treatment for the underlying opportunistic infection is essential. In addition, anti-inflammatory or immunomodulatory therapy may be considered, particularly in severe cases. Corticosteroids, the only treatment for which clinical trial data exist (for treating paradoxical tuberculosis-associated IRIS), are the treatment most frequently used in IRIS. Limited anecdotal reports of benefit exist for other agents, including NSAIDs, pentoxifylline, montelukast, thalidomide, and hydroxychloroquine. Therapeutic procedures (eg, aspiration of pus collections) play an important role in some patients. Interruption of ART may be considered in life-threatening forms of IRIS.
Similar content being viewed by others
References and Recommended Reading
French MA: HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009, 48:101–107.
Riddell JT, Kaul DR, Karakousis PC, et al.: Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med 2007, 5:50.
Burman W, Weis S, Vernon A, et al.: Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007, 11:1282–1289.
Meintjes G, Rangaka MX, Maartens G, et al.: Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009, 48:667–676.
Bicanic T, Harrison T, Niepieklo A, et al.: Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006, 43:1069–1073.
Drake A, Mijch A, Sasadeusz J: Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004, 39:129–132.
Baker JV, Boulware DR, Bohjanen PR: A case for treating high hepatitis B DNA levels before starting HIV therapy. AIDS 2006, 20:2402–2403.
Hardwick C, White D, Morris E, et al.: Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 2006, 82:513–514.
Lesho E: Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006, 4:469–478.
McGee S, Hirschmann J: Use of corticosteroids in treating infectious diseases. Arch Intern Med 2008, 168:1034–1046.
Lawn SD, Bekker LG, Miller RF: Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5:361–373.
Meintjes G, Wilkinson RJ, Morroni C, et al.: Randomized placebo-controlled trial of prednisone for the TB immune reconstitution inflammatory syndrome [abstract 34]. Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.
Pepper DJ, Marais S, Maartens G, et al.: Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009, 48:e96–e107.
Tan K, Roda R, Ostrow L, et al.: PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009, 72:1458–1464.
Rajeswaran G, Becker JL, Michailidis C, et al.: The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: appearances in 11 patients. Clin Radiol 2006, 61:833–843.
Tuon FF, Mulatti GC, Pinto WP, et al.: Immune reconstitution inflammatory syndrome associated with disseminated mycobacterial infection in patients with AIDS. AIDS Patient Care STDS 2007, 21:527–532.
Dautremer J, Pacanowski J, Girard PM, et al.: A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis. AIDS 2007, 21:381–382.
Lortholary O, Fontanet A, Memain N, et al.: Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005, 19:1043–1049.
Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al.: Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002, 81:213–227.
Clark BM, Krueger RG, Price P, French MA: Compartmentalization of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis. AIDS 2004, 18:1218–1221.
Sumner CJ, Newman M, Jay CA: Recurrent myelopathy after HAART in a patient with spinal mycobacterial infection. Neurology 2003, 61:139–140.
Gray F, Bazille C, Adle-Biassette H, et al.: Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005, 11(Suppl 3):16–22.
Du Pasquier RA, Kuroda MJ, Zheng Y, et al.: A prospective study demonstrates an association between JC virusspecific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004, 127:1970–1978.
Du Pasquier RA, Koralnik IJ: Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003, 9(Suppl 1):25–31.
Silva MT, Pacheco MC Jr, Vaz B: Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. AIDS 2006, 20:469–471.
Berger JR: Steroids for PML-IRIS. A double-edged sword? Neurology 2009, 72:1454–1455.
Henderson HW, Mitchell SM: Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999, 83:540–545.
Karavellas MP, Lowder CY, Macdonald C, et al.: Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998, 116:169–175.
Manabe YC, Campbell JD, Sydnor E, Moore RD: Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007, 46:456–462.
McComsey GA, Whalen CC, Mawhorter SD, et al.: Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001, 15:321–327.
Elliott AM, Luzze H, Quigley MA, et al.: A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 2004, 190:869–878.
Venkataramana A, Pardo CA, McArthur JC, et al.: Immune reconstitution inflammatory syndrome in the CNS of HIVinfected patients. Neurology 2006, 67:383–388.
Volkow PF, Cornejo P, Zinser JW, et al.: Life-threatening exacerbation of Kaposi’s sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS 2008, 22:663–665.
Dalessandro L, Bottaro E: Reactivation of CMV retinitis after treatment with subtenon corticosteroids for immune recovery uveitis in a patient with AIDS. Scand J Infect Dis 2002, 34:780–782.
AIDS Info: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Available at http://AIDSinfo.nih.gov. Accessed April 2009.
Fernandes GC, Vieira MA, Lourenco MC, et al.: Inflammatory paradoxical reaction occurring in tuberculosis patients treated with HAART and rifampicin. Rev Inst Med Trop Sao Paulo 2002, 44:113–114.
Bekker LG, Haslett P, Maartens G, et al.: Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2000, 181:954–965.
Schoeman JF, Springer P, van Rensburg AJ, et al.: Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004, 19:250–257.
Schoeman JF, Fieggen G, Seller N, et al.: Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 2006, 21:301–308.
Roberts MT, Mendelson M, Meyer P, et al.: The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect 2003, 47:251–255.
John M, French MA: Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998, 169:473–474.
Bell HC, Heath CH, French MA: Pulmonary Mycobacterium celatum immune restoration disease: immunopathology and response to corticosteroid therapy. AIDS 2005, 19:2047–2049.
Wallis RS, Johnson JL, Okwera A, et al.: Pentoxifylline in human immunodeficiency virus-positive tuberculosis: safety at 4 years. J Infect Dis 1998, 178:1861.
Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW: Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 2004, 18:1223–1224.
Lipman MC, Carding SK: Successful drug treatment of immune reconstitution disease with the leukotriene receptor antagonist, montelukast: a clue to pathogenesis? AIDS 2007, 21:383–384.
Peters-Golden M, Canetti C, Mancuso P, Coffey MJ: Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2005, 174:589–594.
Jarvis B, Markham A: Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000, 59:891–928.
Blackmore TK, Manning L, Taylor WJ, Wallis RS: Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008, 47:e83–e85.
Pires A, Nelson M, Pozniak AL, et al.: Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. J Immune Based Ther Vaccines 2005, 3:7.
Michailidis C, Pozniak AL, Mandalia S, et al.: Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005, 10:417–422.
El-Bradey MH, Cheng L, Song MK, et al.: Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach. Retina 2004, 24:376–382.
Bicanic T, Brouwer AE, Meintjes G, et al.: Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009, 23:701–706.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marais, S., Wilkinson, R.J., Pepper, D.J. et al. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 6, 162–171 (2009). https://doi.org/10.1007/s11904-009-0022-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11904-009-0022-z